Durvalumab to reduce risk of death from lung cancer?

Dhaka,  Wed,  24 May 2017
Published : 12 May 2017, 17:52:48
printer

Durvalumab to reduce risk of death from lung cancer?

Durvalumab to reduce risk of death from lung cancer?
A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced the risk of death from advanced lung cancer, giving it a lead over rivals as it seeks to transform its oncology business.

The trial results are an unexpectedly early boost for the product, known commercially as Imfinzi, which the company hopes will become a blockbuster drug.

Analysts said the results of the trial, known as PACIFIC, showed AstraZeneca was ahead of competitors as there was a gap in the market for such treatment. It also augured well for another trial due in mid-2017 which could mean the drug could be used in combination in newly diagnosed cases.

The drug works by helping the body's immune cells kill cancer, offering an alternative to chemotherapy.

The trial found that durvalumab "significantly reduces risk of disease worsening or death" in forms of lung cancer which are difficult to operate on but have not spread. In this trial it was used after chemotherapy or radiation therapy, according to an online news portal.
ADDRESS
Editor : A.H.M Moazzem Hossain
Published by the Editor for International Publications Limited from Tropicana Tower (4th floor), 45, Topkhana Road, GPO Box : 2526 Dhaka- 1000 and printed by him from City Publishing House Ltd., 1 RK Mission Road, Dhaka-1000.
Telephone : PABX : 9553550 (Hunting), 9513814, 7172017 and 7172012 Fax : 880-2-9567049
Email : editor@thefinancialexpress-bd.com, fexpress68@gmail.com
Copyright © 2017. All rights reserved
Powered by : orangebdlogo
close